A prospective study of serum microbial translocation biomarkers and risk of AIDS-related non-Hodgkin lymphoma [1] [2] [3] . Although the incidence of AIDS-associated NHL (AIDS-NHL) has decreased with combination antiretroviral therapy (cART), it still results in 23-30% of AIDSrelated deaths in countries with readily accessible cART [4] [5] [6] [7] . There are several AIDS-NHL subtypes; all are of B-cell origin, yet subtypes are thought to differ in their pathogenesis [8] [9] [10] . Primary central nervous system lymphomas (PCNSLs) are less common, but more aggressive, than Burkkit's lymphoma, diffuse large B-cell lymphoma (DLBCL), or other systemic tumors [11] . Two major mechanisms are believed to contribute to the genesis of AIDS-NHL: the loss of immunoregulatory control of Epstein-Barr virus (EBV)-infected B cells, resulting from impaired T-cell function; and chronic B-cell activation, which leads to DNA-modifying events (oncogene mutations and translocations) that contribute to lymphomagenesis [12] [13] [14] .
Epidemiologic evidence suggests a role for B-cell stimulatory cytokines and molecules in the development of AIDS-NHL. Elevated levels of circulating cytokines [IL6, IL10, CXCL13, tumor necrosis factor-a (TNFa), interferon-Y-inducible protein (IP-10)/CXCL10], soluble receptors (sCD23, sCD27, sCD30), and markers of inflammation and immune activation (neopterin, k and l immunoglobulin-free light chains) have been shown to precede the development of AIDS-NHL by up to 7 years [11, 15] . Examining potential sources of chronic B-cell activation in the setting of HIV infection may provide insights into the etiology of AIDS-NHL. Microbial components [e.g. lipopolysaccharide (LPS)] passing across the intestinal epithelial barrier into peripheral circulation (termed microbial translocation) has been shown to contribute to systemic immune activation in chronic HIV infection, and may be a contributor to the chronic B-cell activation that predisposes to AIDS-NHL [16, 17] . Microbial translocation and the consequential systemic immune activation is influenced by the loss of integrity and structural damage to the gastrointestinal barrier in chronic HIV infection, which can be measured by circulating barrier proteins including fatty acid-binding protein (FABP) 2 and haptoglobin [17, 18] . The presence of LPS in the bloodstream leads to consumption of antibodies against LPS (antiendotoxin-core protein IgM, otherwise known as EndoCAb), increased production of LPS-binding protein (LBP) and receptor (sCD14), and increase in activation of macrophages and the secretion of numerous cytokines and chemokines.
In this study, we sought to determine the association between these biomarkers of microbial translocation, intestinal integrity, and macrophage activation and subsequent AIDS-NHL development, to support our hypothesis that microbial translocation contributes to chronic B-cell activation and AIDS-NHL risk. We also examined several B-cell activation markers to confirm prior reports of significant elevations preceding AIDS-NHL diagnosis.
Methods

Study population
This is a nested case-control study utilizing serum specimens from participants in the Multicenter AIDS Cohort Study (MACS), an ongoing prospective study of the natural and treated history of HIV/AIDS in men who report sex with men [19, 20] . The participants were recruited from four US metropolitan areas (Baltimore/ Washington, Chicago, Los Angeles, and Pittsburgh), and study visits have been held at 6-month intervals beginning in 1983 (www.statepi.jhsph.edu/macs/macs.html). A total of 7350 men have been enrolled in the MACS.
Participants were selected for the present study on the basis of pathologically confirmed AIDS-NHL after enrollment into the MACS and the availability of archival serum specimens prior to cancer diagnosis (n ¼ 200). For each case, one control was selected randomly from all possible HIV-infected MACS participants who had not developed AIDS-NHL as of November 2014, matched on: CD4 þ T-cell counts (AE200 cells/ml); prior antiretroviral drug use (ever versus never); and recruitment year into the cohort (1984-1985, 1987-1991, or 2001þ) . Additionally, cases treated with a potent combination of antiretroviral drugs were matched to controls on time since first therapy, and cases who became HIV-infected after recruitment into the cohort were matched to controls by their seroconversion date.
Biomarker determination
Serum levels of haptoglobin (R&D Systems, Minneapolis, Minneapolis, USA) and antiendotoxin-core protein IgM (Hycult Biotech, Uden, The Netherlands) were determined by ELISA according to the manufacturer's directions. Serum levels of all other biomarkers were determined using the Luminex (Austin, Texas, USA) platform with custom-made panels produced by R&D Systems. Briefly, Luminex microparticles precoated with analyte-specific antibodies were incubated with diluted serum samples, followed by a biotin antibody and by a streptavidin-phycoerythin conjugate. The fluorescence intensity of each analyte's microparticles was quantified using a Bioplex 200 (Luminex) System Analyzer (BioRad, Hercules, California, USA), and the data analyzed using BioPlex Manager (v 4.1.1) software. The lower limit of detection (LLD) for each biomarker was set either as the lowest value that the BioPlex Manager software could calculate using the standard curve, or as the lowest value of the standard curve, whichever was smaller. For quality control, case and control samples were equally distributed across reaction plates, and replicates were included across the reaction plates to calculate coefficients of variation. All laboratory personnel were blinded to the case-control status of samples. Additional assay details including LLD, dilution factors, detectable fractions, and coefficients of variations, are presented in Supplemental Table 1 , http://links.lww.com/QAD/B230.
Statistical analysis
We analyzed our biomarkers as natural log-transformed continuous variables. Additionally, in exploratory analyses, we examined biomarker categories by quartiles according to the distribution among the controls. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) representing the risk of AIDS-NHL associated with one log-unit change in biomarker levels or risk of AIDS-NHL associated with each of the second, third, and fourth quartiles compared with the first quartile, using conditional logistic regression. In addition to the matching factors, ORs were adjusted for covariates selected a priori for their association with AIDS-NHL in prior studies including age (continuous), race/ethnicity (categorical), and hepatitis C virus (HCV) infection status. Each biomarker was tested for association with AIDS-NHL in separate regression models. Additionally, we tested for trends across quartiles using a continuous variable with values representing the medians of each category. We examined patterns of AIDS-NHL risk associated with biomarkers according to subgroups of systemic lymphomas or PCNSL. We also examined patterns of AIDS-NHL risk associated with biomarkers according to the time interval between serum sample collection and AIDS-NHL diagnosis. We classified this lag time into two categories: less than 4 years or at least 4 years. These categories were selected according to the natural distribution of lag times and wanting to ensure an approximately equal number of participants in each category. In addition to these stratified analyses, we also tested for statistical interactions between biomarkers and lag time using interaction terms in the models. Lastly, we calculated pairwise correlations between all biomarkers using Pearson's correlation coefficient.
Results
Study population description
Cases and controls were similar in their distributions by recruitment year, CD4
þ T-cell count, and antiretroviral drug therapy, as expected based on the matched design ( Table 1 ). The majority of controls and cases were nonHispanic white (80 and 81%, respectively). Cases tended to be older than controls, with 44.5% of cases at least 40 years, compared with 38% of controls. Cases were more likely to have acute or chronic HCV infection compared with controls (10.2 versus 6.5%). Both groups had relatively high levels of CD4 þ T cells, with 51.5% of controls and 46.5% of cases having more than 400 CD4 þ T cells/ml, and the majority were antiretroviral drugnaïve (94% of controls and 94.5% of cases). The mean time from serum date to NHL diagnosis was 3.9 years; SD of 1.6 years and a range of 1 month to 12 years. The majority of cases (69.5%) were systemic lymphomas, and DLBCL was the major subtype (48.2%).
Microbial translocation biomarkers
Levels of sCD14, FABP2, and LBP were associated with AIDS-NHL risk, with 3.71-fold, 1.64-fold, and 2.97-fold increases in risk for each unit increase on the natural log scale, respectively ( Table 2 and Fig. 1 ). Additionally, participants with marker levels in the highest versus lowest quartile for haptoglobin, and EndoCAb, were at 2.18-fold increased, and 2-fold decreased risk of AIDS-NHL, respectively. For some markers (haptoglobin, FABP2, and LBP), there appeared to be a threshold effect for the highest quartile: an increased AIDS-NHL risk was only observed for participants with marker levels in the highest versus lowest quartiles. In comparison, for sCD14, AIDS-NHL risk was elevated similarly across the second, third, and fourth quartiles. Also, AIDS-NHL risk was reduced similarly across the second, third, and fourth quartiles for EndoCAb.
In subgroup analyses by lag time between prediagnostic serum collection date and AIDS-NHL diagnosis date, EndoCAb, FABP2, and haptoglobin demonstrated consistent associations with AIDS-NHL risk across lag times, whereas other markers were more strongly associated with AIDS-NHL risk when measured close to diagnosis date (<4 years, sCD14 and LBP, Table 2 ). There was an association between increased AIDS-NHL risk and higher levels of FABP2, haptoglobin, and LBP, particularly among those men with systemic lymphoma in comparison with those with PCNSL ( Fig. 1 , Supplemental Table 2 , http://links.lww.com/QAD/ B230). Conversely, higher levels of sCD14 were more strongly associated with PCNSL versus systemic lymphoma. EndoCAb appeared to be similarly associated with decreased risk of systemic lymphoma and PCNSL.
Macrophage-associated cytokines and chemokines BAFF, CCL17, ICAM, IL18, and MCP1 were associated with AIDS-NHL, with 2.21-fold, 1.68-fold, 1.66-fold, 1.93-fold, and 1.60-fold increases in risk for each unit increase on the natural log scale, respectively (Table 3, Figure 1 ). Whenever modeled as quartiles, these biomarkers generally displayed dose-response relationships with AIDS-NHL risk (the higher the levels, the higher the risk). For sCD163, participants with levels in the highest versus lowest quartile were at 1.94-fold increased AIDS-NHL risk. CCL17 and MCP1 displayed similar associations with AIDS-NHL risk whenever measured less than 4 years or at least 4 years prior to diagnosis date (Table 3) . BAFF and IL18, were more strongly associated with AIDS-NHL risk whenever measured close to diagnosis date (<4 years), whereas ICAM and sCD163 displayed stronger associations whenever measured at least 4 years prior to diagnosis. BAFF and IL18 also displayed stronger associations with systemic lymphoma than PCNSL, whereas CCL17, ICAM, MCP1 (Supplemental Table 2 , http://links.lww. com/QAD/B230) were similarly associated with systemic and PCNSL risks. TRAIL was unassociated with AIDS-NHL overall; however, we observed a statistically significant interaction (P ¼ 0.04) between TRAIL and lag time: higher TRAIL levels were associated with AIDS-NHL risk only whenever measured at least 4 years prior to AIDS-NHL diagnosis.
B-cell activation markers
There was a significant association between B-cell activation markers with AIDS-NHL risk, with ORs ranging from 1.23 to 4.91 for each unit increase on the natural log scale (Supplemental Table 3 , http:// links.lww.com/QAD/B230, Fig. 1 ). These associations were observed whenever markers were measured close to diagnosis (<4 years), and persisted whenever markers were measured at least 4 years prior to diagnosis. These biomarkers were significantly associated with both systemic lymphoma and PCNSL, although CXCL13 appeared to be more strongly associated with systemic lymphoma whereas sCD23 was more strongly associated with PCNSL (Supplemental Table 2 , http://links.lww. com/QAD/B230, Fig. 1 ).
We observed strong correlations between several markers of microbial translocation (sCD14), macrophage activation (sCD163, ICAM, BAFF, and IL18), and B-cell The reference date for these variables is the blood collection date, which was used for testing serum biomarkers.
activation (IP10 and sCD27), with Pearson's pairwise correlations ranging from 0.3 to 0.6.
Discussion
In this prospective study, we defined the association between serum levels of molecules associated with microbial translocation and immune activation/ inflammation with subsequent AIDS-NHL diagnosis. Key novel observations were that markers of bacterial exposure and host response to bacteria (sCD14, LBP, EndoCAb), intestinal barrier dysfunction (FABP2 and haptoglobin), and macrophage activation (BAFF, CCL17, ICAM, IL18, MCP1, and sCD163,) were highly Table 2 . Association between microbial translocation biomarkers and AIDS-associated non-Hodgkin lymphoma risk overall and stratified by time from blood collection to AIDS-associated non-Hodgkin lymphoma diagnosis. ORs were adjusted for age at serum sample date (continuous), race/ethnicity (categorical), and HCV infection status at serum sample date. AIDS-NHL, AIDS-associated non-Hodgkin lymphoma; CI, confidence interval; HCV, hepatitis C virus; N, number; OR, odds ratio. Fig. 1 . Overall AIDS-associated non-Hodgkin lymphoma, systemic lymphoma, and primary central nervous system lymphoma risk associated with one unit increase in biomarkers on the natural log scale (OR, box; 95% CI, bar). CI, confidence interval; OR, odds ratio.
predictive of subsequent AIDS-NHL diagnosis in men with HIV infection. Importantly, these associations were observed after careful adjustment of HIV disease status, immune suppression, and antiretroviral drug therapy.
sCD14 displayed the strongest association with AIDS-NHL of all the microbial translocation markers examined. sCD14 is the soluble form of the LPS co-receptor and is produced by macrophages on exposure to LPS and other inflammatory activators [21, 22] . Furthermore, sCD14
was more strongly associated with AIDS-NHL when measured close to the diagnosis date (<4 years), and was more strongly associated with PCNSL than systemic lymphoma. PCNSL is an aggressive presentation of AIDS-NHL believed to arise principally because of the oncogenic properties of uncontrolled EBV reactivation in severely immunocompromised individuals. These observations are consistent with the hypothesis that microbial translocation is a consequence of compromised gut immunity (lower CD4 þ T-cell count), which occurs close ORs were adjusted for age at serum sample date (continuous), race/ethnicity (categorical), and HCV infection status at serum sample date. AIDS-NHL, AIDS-associated non-Hodgkin lymphoma; CI, confidence interval; HCV, hepatitis C virus; N, number; OR, odds ratio.
to the time of AIDS-NHL diagnosis [23] , and is more strongly associated with PCNSL in comparison with systemic lymphoma development [24] . In a prior study, serum levels of sCD14 greater than or equal to 1.76 Â 10 6 pg/ml (median value in controls) were associated with a 2.7-fold increased risk of AIDS-NHL, in samples collected a median of 1 year prior to AIDS-NHL diagnosis [25] . Our results build on this prior observation in a larger study sample with a longer lag time from specimen collection to AIDS-NHL diagnosis.
LBP was another biomarker found to be strongly associated with subsequent AIDS-NHL diagnosis, particularly when it was measured close to NHL diagnosis date (<4 years); however, in contrast to sCD14, LBP was more strongly associated with systemic lymphoma compared with PCNSL. LBP is an LPS-binding protein, which promotes binding of LPS to its receptor. Additionally, we observed that levels of EndoCAb, a neutralizing antibody against LPS, were significantly reduced prior to AIDS-NHL, with consistent associations across lag times from blood collection to AIDS-NHL diagnosis, and between systemic lymphoma and PCNSL. In prior studies, LBP and EndoCAb have been described as indirect markers of LPS: LBP is positively associated whereas EndoCAb is inversely associated with LPS levels [16] . Prior research suggests that HIV infection impairs EndoCAb response [26] . Thus, the observed inverse association between EndoCAb levels and AIDS-NHL risk is consistent with the notion that LPS in circulation among HIV-infected persons at risk for NHL depletes circulating EndoCAb, further supporting the hypothesized role of microbial translocation in AIDS-NHL.
Structural damage to the gastrointestinal tract in chronic HIV infection has been well described [18] , and the integrity of the intestinal barrier is an important factor in HIV-related systemic immune activation that may also influence lymphomagenesis [17] . FABP2 (a lipid transport protein and marker of enterocyte damage) and haptoglobin (a physiological modulator of intercellular tight junctions) are markers of intestinal barrier integrity. For both of these markers, a significantly increased risk for AIDS-NHL was observed only among those men with the highest levels (fourth quartile), particularly for systemic lymphoma. In prior studies, higher levels of FABP2 were seen to be associated with lower CD4 þ T-cell counts, liver disease progression, and mortality in HIV infection [27] [28] [29] . To our knowledge, no prior studies have examined serum haptoglobin in HIV infection or lymphoma.
We previously showed that pre-NHL diagnosis serum levels of markers related to B-cell activation (sCD23, sCD27, CXCL13, IL6, IL10, IP10, and TNFa) were associated with risk for AIDS-NHL [11, 13, 15, 30] . In this study, we found that other cytokines and chemokines that are mainly secreted by activated macrophages (BAFF, CCL17, ICAM, IL18, MCP1, and sCD163) were associated with risk for AIDS-NHL [31] [32] [33] [34] [35] . Macrophages have numerous functions related to inflammation, immunity, and tumor growth, and can be phenotypically polarized by the microenvironment to become M1 or M2. M1 typically secrete pro-inflammatory cytokines (TNFa, IL-6), whereas M2 mainly promote Th2 responses, immunosuppression, and tumor promotion [31, 36] . It is interesting to note that many of the cytokines or chemokines associated with AIDS-NHL risk are typically produced by M1-polarized macrophages, including IP10, TNFa, IL18, IL6, and BAFF [31, 32, 36] , which may be reflecting microbial translocation and activation of macrophages by LPS. Some notable M2 markers, including CCL17 and CD163 [31, 36] , were also associated with AIDS-NHL risk, possibly reflecting the presence of tumor-associated, tumor growth-promoting, macrophages. However additional studies are needed to elucidate these associations.
Interestingly, we found an association between prediagnosis serum levels of CCL17 (TARC) and the risk for AIDS-NHL. CCL17 was previously shown to be associated with the development of Hodgkin lymphoma, suggesting that there may be common mechanisms contributing to the development of these lymphatic system cancers as they relate to CCL17 [37] . High levels of sCD163 (fourth quartile) were associated with increased AIDS-NHL risk, particularly PCNSL (which tend to be EBV-associated). In prior work, sCD163 correlated with plasma EBV-DNA in patients with Hodgkin lymphoma [38] . Thus, we hypothesize that CCL17 and sCD163 may be associated with EBV reactivation in AIDS-NHL and Hodgkin lymphoma.
We also found that prediagnosis levels of BAFF were associated with risk for AIDS-NHL. BAFF is a member of the TNF family of cytokines and plays an important role in normal B-cell proliferation and activation. High levels of soluble BAFF may be contributing to prolonged B-cell survival and increased susceptibility to mutation and transformation [39] . Prior studies have found that BAFF was elevated in patients with NHL and correlated with aggressive disease [40] .
The question of whether microbial translocation and macrophage activation markers are etiologically associated with AIDS-NHL development is impossible to determine in the context of an observational study. Interestingly, sCD14 was highly correlated with B-cell activation markers (sCD27 and IP10), providing a link between microbial translocation and the B-cell activation that precedes AIDS-NHL. However, preclinical disease in the cases may be responsible for the observed associations. Interestingly, we found that risk estimates for many of our markers were comparable when analyses were stratified by short (<4 years) or long (!4 years) lag time from specimen collection to AIDS-NHL diagnosis, suggesting that the associations are less likely to be because of undiagnosed disease. Some notable exceptions were sCD14 and LBP, both of which were more strongly associated with AIDS-NHL when measured closer to NHL diagnosis, suggesting a role of undiagnosed AIDS-NHL in the observed associations.
Systemic immune activation occurs early in the course of HIV infection [16, 17] . Therefore, it is reasonable to speculate that a failure to control immune activation may contribute to lymphomagenesis. In accordance with this, a recent study showed that plasma levels of LBP, FABP2, and IL6 were significantly elevated in patients for whom antiretroviral drug treatment was introduced during chronic HIV infection. In contrast, patients who started treatment with a potent combination of antiretroviral drugs at the time of HIV diagnosis were able to normalize their levels of LBP, FABP2, and IL6 [41] . This finding supports early introduction of therapy to limit systemic immune activation and thereby reduce the incidence of lymphomagenesis. Even though this is an interesting hypothesis, we were not able to test it in this study, as only a small percentage of cases and controls (6%) were treated with potent combinations of antiretroviral drugs.
The main strength of this study is the inclusion of a large sample of known AIDS-NHL cases with detailed longitudinal covariate data and specimen availability before AIDS-NHL. Compared with prior studies, we examined a larger number of biomarkers indicative of microbial translocation and related immune activation, with longer lag times from biomarker measurement to AIDS-NHL diagnosis. Also, our larger study population allowed us to examine differences in biomarker associations by lag time and site (CNS versus systemic). In addition to the markers presented in this article, this study population has been characterized with respect to a number of important biomarkers related to AIDS-NHL, permitting us to evaluate our findings in this context. Although we controlled for CD4 þ T-cell numbers and date of HIV infection among seroconverters, our observed associations may still be influenced by residual confounding by HIV progression. Also, our population consisted largely of white MSM, who developed lymphoma prior to initiation of HAART, potentially limiting the generalizability of the findings. We did not correct for type-1 error, thus we cannot exclude the possibility of chance findings. However, our goal of this study was to examine several biomarkers in a related pathway to demonstrate strength of evidence (not necessarily statistical significance for a single biomarker) for a role of microbial translocation in AIDS-NHL, thus type-1 error correction may not be appropriate.
Here we show that systemic immune activation in chronic HIV infection plays a prominent role in the development of AIDS-NHL. Additionally, the cytokine profile seen to precede AIDS-NHL diagnosis is consistent with an M1 macrophage activation, which in part may be driven by endotoxin exposure because of microbial translocation. Future research is needed to better understand their biologic basis. For example, studies are needed to better define how LPS drives chronic B-cell activation and subsequent AIDS-NHL development. If these results are replicated, attenuation of microbial translocation-induced immune activation could be an effective therapeutic strategy to reduce AIDS-NHL risk.
